Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | HPGDS | O60760 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829788 | 0.89 | AKR1C3 (0.83) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL16026545 | 0.89 | PKM (0.74) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL3904994 | 0.87 | KMT2A (0.68) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL1423195 | 0.86 | AKR1C3 (0.66) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL30747784 | 0.86 | TSHR (0.68) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL8362372 | 0.86 | TSHR (0.68) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL14344837 | 0.84 | DRD2 (0.63) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL9272910 | 0.83 | TSHR (0.64) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL14758395 | 0.83 | ALDH1A1 (0.81) | AKR1C3TSHRKMT2AMEN1POLB | |
| SCHEMBL7572432 | 0.83 | LMNA (0.65) | AKR1C3TSHRKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-9724381-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170049849-A9 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-02-23 | — | — | US | disclosed |
| US-20150031605-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | UNIV TULANE (US) | 2015-01-29 | — | — | US | disclosed |
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | disclosed |
| US-8569267-B2 | Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| US-8536120-B2 | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536120-B2 | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-09-17 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-0796251-B1 | URACIL DERIVATIVES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2001-10-17 | — | — | EP | disclosed |
| US-6046329-A | Uracil derivatives | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-04-04 | — | — | US | disclosed |
| EP-0796251-A1 | URACIL DERIVATIVES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1997-09-24 | — | — | EP | disclosed |
| WO-1996017831-A1 | URACIL DERIVATIVES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | AKR1C3 1098/4885TSHR 179/4885KMT2A 1892/4885 |
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | AKR1C3 1516/4885TSHR 487/4885KMT2A 3994/4885 |
| US-20150031605-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | AKR1C3 479/4885TSHR 22/4885KMT2A 3300/4885 |
| US-20170049849-A9 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | AKR1C3 479/4885TSHR 22/4885KMT2A 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.